Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · S

S. 1416 (116th)

Affordable Prescriptions for Patients Act of 2019

openUnited States· United States Congress· EN

Introduced

9 May 2019

Last action

28 June 2019 · Reported

Status

Placed on Senate Legislative Calendar under General Orders. Calendar No. 132.

Sponsors

Sen. Cornyn, John [R-TX], Sen. Blumenthal, Richard [D-CT], Sen. Capito, Shelley Moore [R-WV], Sen. Murray, Patty [D-WA], Sen. Scott, Rick [R-FL], Sen. Kennedy, John [R-LA], Sen. Hawley, Josh [R-MO], Sen. Durbin, Richard J. [D-IL], Sen. King, Angus S., Jr. [I-ME], Sen. Smith, Tina [D-MN], Sen. Peters, Gary C. [D-MI], Sen. McSally, Martha [R-AZ], Sen. Fischer, Deb [R-NE], Sen. Toomey, Patrick [R-PA]

Subjects

Discovery layer

Source updated

10 August 2026

Official sourceDownload fileView documentsShare

Summary

Affordable Prescriptions for Patients Act of 2019 This bill prohibits patent thicketing and product hopping by drug manufacturers. In general, patent thicketing occurs when a drug manufacturer obtains new patents related to a previously-patented drug, biological product, or underlying chemical composition that extends the manufacturer’s market exclusivity for that drug without demonstrating that the new patents serve a meaningful purpose other than limiting competition from generic drug manufacturers. Product hopping is presumed when a drug manufacturer obtains removal of a drug from the Food and Drug Administration’s approved drug list, discontinues a drug, or markets a reformulation of an already-approved drug during a certain period after which the manufacturer has been notified that a competing drug manufacturer has applied for generic drug approval. These practices are not considered product hopping if the manufacturer demonstrates that the drug was removed from the approved-drug list for safety reasons. Or, in the case of a drug reformulation, the manufacturer shows that the modified product provides a significant health benefit, is the option least likely to reduce competition, and is based on substantial financial considerations unrelated to limiting competition. The Federal Trade Commission may penalize violating manufacturers and bring claims in federal court to prohibit the conduct and provide restitution.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 9 May 2019

    Introduced

    Read twice and referred to the Committee on the Judiciary.

    Source: IntroReferral

  2. 9 May 2019

    Introduced

    Introduced in Senate

    Source: IntroReferral

  3. 27 June 2019

    Reported

    Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.

    Source: Committee

  4. 28 June 2019

    Calendars

    Placed on Senate Legislative Calendar under General Orders. Calendar No. 132.

    Source: Calendars

  5. 28 June 2019

    Reported

    Committee on the Judiciary. Reported by Senator Graham with an amendment in the nature of a substitute. Without written report.

    Source: Committee

  6. 28 June 2019

    Reported

    Committee on the Judiciary. Reported by Senator Graham with an amendment in the nature of a substitute. Without written report.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

6 official files

Reported to Senate (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Reported to Senate (text)

    Reported to Senate · EN · 28 June 2019

    ViewDownloadOpen at official source

  • Reported to Senate (PDF)

    Reported to Senate · EN · 28 June 2019

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Reported to Senate

    summary · EN · 28 June 2019

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in Senate (text)

    Introduced in Senate · EN · 9 May 2019

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in Senate (PDF)

    Introduced in Senate · EN · 9 May 2019

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in Senate

    summary · EN · 9 May 2019

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.